← All indications
Spondylitis, Ankylosing
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
Drugs by status
Approved for this indication (15)
Phase 4 trials (23)
- diclofenac
- thalidomide
- secukinumab
- naltrexone
- hydroxychloroquine
- imrecoxib
- kunxian
- loxoprofen
- meloxicam
- pamidronate
- alendronic acid
- acetaminophen
- sulfasalazine
- tramadol
- methotrexate
- paeony glucosides
- rebamipide
- sodium chloride
- varicella zoster virus glycoprotein e antigen
- benzathine penicillin
- fengshigutong
- Eupatilin
- yuxuebi
Phase 3 trials (23)
Phase 2 trials (23)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (38)
- AbbVie
- Centocor
- Pfizer
- Wyeth
- Novartis
- Aarhus University
- Bnai Zion Medical Center
- Chung Shan Medical University
- Institut National de la Santé Et de la Recherche Médicale, France
- Rheumatism Foundation Hospital
- Shaoxing Second Hospital
- Universidade Nova de Lisboa
- Chinese University of Hong Kong
- Columbia University
- Fudan University
- Peking University
- Wenzhou Medical University
- University of Copenhagen
- Zhejiang University
- Health and Family Planning Commission of Guangdong
- Jiao Tong University
- François Rabelais University
- University of Toulouse
- Southern Medical University
- J. Dietl Hospital, Krakow
- Sun Yat-Sen University
- Government of China
- Ruhr University Bochum
- University of Sao Paulo
- Jagiellonian University
- +8 more
Organization Involved with Phase 3 Indications (52)
- Eisai
- Celgene
- Galapagos NV
- Amgen
- Gilead Sciences
- Eli Lilly
- Biocad
- Biothera
- Corporacion Parc Tauli
- Hengrui Therapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Parexel
- POZEN
- Sunshine Lake Pharma Co., Ltd.
- Sun Pharmaceuticals
- Boehringer Ingelheim
- Otsuka
- TSH Biopharm Corporation Limited
- Spanish Foundation of Rheumatology
- Ajou University
- Dong-A University
- Gachon University
- Guangzhou Medical University
- Hanyang University
- Hoosier Cancer Research Network
- Hospital Universitario Central de Asturias
- Korea University
- Kyung Hee University
- Seoul National University
- Shanghai University of Traditional Chinese Medicine
- +22 more
Organization Involved with Phase 2 Indications (22)
- Regeneron
- Bristol-Myers Squibb
- Advanced Accelerator Applications
- Sanofi
- AmpliPhi Biosciences Corporation
- Array BioPharma
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Iltoo Pharma
- Shanghai Pharmaceuticals Holding Co., Ltd
- National Center for Research Resources (NCRR)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of London
- Oregon Health and Science University
- Saratov State Medical University
- University of Lausanne
- University of Rochester
- University of Zurich
- University of California, San Francisco
- University of Tabriz
- Tabriz Medical University
- University of Alabama, Birmingham
- University of Paris
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (5)